FIELD: medicine.
SUBSTANCE: invention is related to experimental pharmacology and genetic technologies. A method for correcting muscular dystrophy using plasmid DNA in dysferlin-deficient mice is proposed. Male dysferlin-deficient B6.A/J-Dysfprmd mice are administered a single dose of the drug “ПЛ-ДИСФ-pMHCK7” based on plasmid dysferlin DNA with the “pMHCK7” promoter at a concentration of 0.5 g/l in a volume of 100 mcl, 50 mcl in the right and left m. tibialis anterior. Correction of myodystrophy is confirmed by the results of the “Vertical pole” test 30 days after the administration of “ПЛ-ДИСФ-pMHCK7”.
EFFECT: invention makes it possible to expand the arsenal of drugs for the effective treatment of dysferlinopathies.
1 cl, 3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF MAINTAINING STATIC ENDURANCE IN DYSFERLIN-DEFICIENT MICE IN EXPERIMENT | 2023 |
|
RU2829651C1 |
| METHOD FOR IMPROVING PHYSICAL PERFORMANCE USING ADENO-ASSOCIATED VIRAL VECTOR IN EXPERIMENT ON DYSFERLIN-DEFICIENT MICE | 2023 |
|
RU2828839C1 |
| METHOD OF MYODYSTROPHY CORRECTION USING ADENO-ASSOCIATED VIRAL VECTOR IN EXPERIMENT | 2022 |
|
RU2821544C1 |
| CODON-OPTIMISED CDNA CODING HUMAN DYSFERLIN, GENETICALLY ENGINEERED CONSTRUCT, RECOMBINANT ADENOVIRUS AND PHARMACEUTICAL COMPOSITION FOR TREATING DYSFERLINOPATHIES | 2012 |
|
RU2527073C2 |
| RECOMBINANT PLASMID DNA AAV SYNH1-2_SHRNA FREUD-1, PROVIDING SYNTHESIS OF SHPHK, SUPPRESSING EXPRESSION OF GENE CODING SELECTIVE SILENSER 5-HT1A OF RECEPTOR FREUD-1, IN BRAINS OF MAMMALS | 2019 |
|
RU2726764C1 |
| AGENT PROMOTING THERAPEUTIC ANGIOGENESIS AND METHOD FOR IMPLEMENTATION THEREOF | 2009 |
|
RU2449799C2 |
| GENETIC ENGINEERING STRUCTURE FOR ANGIOGENESIS STIMULATION | 2019 |
|
RU2737487C1 |
| METHOD OF TREATING LAMELLAR ICHTHYOSIS USING A RECOMBINANT ADENO-ASSOCIATED VIRUS BASED ON A GENETIC CONSTRUCT CODING A NUCLEOTIDE SEQUENCE OF A TRANSGLUTAMINASE 1 GENE | 2023 |
|
RU2821567C1 |
| METHOD OF ANGIOGENESIS AUGMENTATION IN ISCHEMIC TISSUES AND COMBINATION DRUG FOR METHOD IMPLEMENTATION | 2015 |
|
RU2628706C2 |
| RECOMBINANT PLASMIN DNA pFGF2, ENCODING A POLYPEPTIDE WITH THE PROPERTIES OF THE MAIN HUMAN FIBROBLAST GROWTH FACTOR AND RECOMBINANT STRAIN OF METHYLOTROPHIC YEAST PICHIA PASTORIS WHICH IS PRODUCER OF POLYPEPTIDE WITH THE PROPERTIES OF THE MAIN FIBROBLAST GROWTH FACTOR | 2021 |
|
RU2804544C2 |
